Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 7/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3093116 | 0.89 | FAAH (0.44) | FAAHTDP1CXCR2LPAR1KMT2A | |
| SCHEMBL3106232 | 0.82 | FAAH (0.46) | FAAHLPAR1 | |
| SCHEMBL3094600 | 0.80 | NPC1 (0.41) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL3093118 | 0.79 | TDP1 (0.62) | TDP1LPAR1KMT2AMEN1CASP1 | |
| SCHEMBL4758367 | 0.77 | FAAH (0.50) | FAAHTDP1KMT2AMEN1ALDH1A1 | |
| SCHEMBL3100600 | 0.77 | TSHR (0.52) | FAAHCXCR2LPAR1KMT2AMEN1 | |
| SCHEMBL3099215 | 0.74 | — | — | |
| SCHEMBL5324746 | 0.72 | FAAH (0.40) | FAAHTDP1KMT2AMEN1CASP1 | |
| SCHEMBL3106238 | 0.72 | TDP1 (0.51) | TDP1LPAR1KMT2AMEN1CASP1 | |
| SCHEMBL3183513 | 0.71 | TSHR (0.68) | FAAHTDP1KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531572-B2 | Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use | XENOPORT, INC. (US) | 2009-05-12 | — | — | US | claimed |
| US-20080051458-A1 | Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use | XENOPORT, INC. | 2008-02-28 | — | — | US | claimed |
| US-7799829-B2 | Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use | XENOPORT, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-20090192225-A1 | Acyloxyalkyl Carbamate Prodrugs of Alpha-Amino Acids, Methods of Synthesis and Use | XENOPORT, INC. (US) | 2009-07-30 | — | — | US | disclosed |
| US-7531572-B2 | Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use | XENOPORT, INC. (US) | 2009-05-12 | — | — | US | disclosed |
| US-20080051458-A1 | Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use | XENOPORT, INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192225-A1 | Acyloxyalkyl Carbamate Prodrugs of Alpha-Amino Acids, Methods of Synthesis and Use | ASNS, ASPH, DNPEP | FAAH 49/4885TDP1 2290/4885CXCR2 3818/4885 |
| US-20080051458-A1 | Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use | ASNS, ASPH, DNPEP | FAAH 49/4885TDP1 2290/4885CXCR2 3818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.